Chronic Obstructive Pulmonary Disease (COPD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Chronic Obstructive Pulmonary Disease (COPD) Market Outlook

Thelansis’s “Chronic Obstructive Pulmonary Disease (COPD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Obstructive Pulmonary Disease (COPD)   treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Chronic Obstructive Pulmonary Disease (COPD) Overview

Chronic Obstructive Pulmonary Disease (COPD) is a significant global contributor to chronic illness and premature death. It afflicts many individuals for extended periods, ultimately leading to early mortality or related complications. As the fourth leading cause of death worldwide, COPD’s prevalence and fatality rates are expected to rise in the coming decades. This condition initiates chronic inflammation, causing structural alterations and constriction in the smaller air passages. Inflammatory processes also contribute to lung tissue damage, resulting in the detachment of alveoli from the smaller airways and a decrease in lung elasticity, ultimately reducing the ability of airways to stay open during exhalation. To assess the extent of airflow restriction, spirometry serves as the most accessible and dependable measure of lung function. The impact of COPD on an individual patient is determined not only by the degree of airflow limitation but also by the severity of associated symptoms. An imperfect correlation exists between the degree of airflow limitation and symptoms. Consequently, spirometric staging is a practical approach intended for implementation, serving as an educational tool and offering a general indication for the initial management plan.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Chronic Obstructive Pulmonary Disease (COPD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034